Christian Weyer M.D., M.A.S. — Executive Vice President of Research & Development at Intercept Pharmaceuticals

Dr. Christian Weyer, also known as Chris, M.D., MAS-CLRE has been Executive Vice President of Research & Development at Intercept Pharmaceuticals, Inc. since November 27, 2017. Dr. Weyer served as President and Chief Development Officer at Profil Institute for Clinical Research, Inc from December 1, 2015 to 2017. Dr. Weyer oversaw the clinical development services and forge new strategic partnerships with biopharmaceutical companies and other stakeholder groups and clinical development programs or licensing opportunities for metabolic drug or device candidates. Dr. Weyer is globally recognized as an accomplished business leader with scientific expertise in diabetes and obesity through his work in academia, government research and the biopharmaceutical settings. Dr. Weyer's career in metabolic drug development spans more than 20 years, involving clinical studies and regulatory submissions at all stages of product development and across the continuum of diabetes, obesity and NAFLD/NASH. Following training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of D??sseldorf, Germany, Dr. Weyer worked at the National Institutes of Health, NIDDK, conducting clinical research on the pathogenesis of obesity and type 2 diabetes. Dr. Weyer served as the Chief Executive Officer and President at Fate Therapeutics, Inc. from October 2012 to November 30, 2015. Dr. Weyer served as Senior Vice President of Research & Development at Amylin Pharmaceuticals, Inc. since June 2010. He served as Vice President of Corporate Development - Diabetes & Obesity for Amylin Pharmaceuticals Inc. since August 2008. He joined Fate after a 12-year tenure with Amylin Pharmaceuticals, Inc. He joined Amylin Pharmaceuticals Inc. in January 2001 as Director of Medical Affairs, he held various R&D positions and served as Vice President of Clinical Research. Dr. Weyer was a Visiting Scientist with the National Institutes of Health, NIDDK, in Phoenix, AZ from 1997 to 2001, where he conducted clinical research on the pathophysiology of obesity and type 2 diabetes in Pima Indians. He serves on the program's advisory board. He serves as Member of the Scientific Advisory Board at Receptos, Inc. He was a Director of Fate Therapeutics, Inc. since October 2012. He received his MD and clinical training at the Dept. of Metabolic Disorders, WHO Collaborating Center for Diabetes Treatment and Prevention, at the University of D??sseldorf, Germany. Dr. Weyer also holds a postdoctoral master's degree in advanced clinical research from the University of California, San Diego. .